In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

De novo mutation rate in patients with hypertrophic cardiomyopathy and left ventricular non-compaction.

Session Comorbidities and cardiomyopathies - How to manage?

Speaker Elena Zaklyazminskaya

Event : Heart Failure 2018

  • Topic : basic science
  • Sub-topic : Basic Science - Cardiac Biology and Physiology: Genetics, Epigenetics, ncRNA
  • Session type : Rapid Fire Abstracts

Authors : E Zaklyazminskaya (Moscow,RU), M Polyak (Moscow,RU), A Bukaeva (Moscow,RU), G Radzhabova (Moscow,RU), S Dzemeshkevich (Moscow,RU)

E Zaklyazminskaya1 , M Polyak1 , A Bukaeva1 , G Radzhabova1 , S Dzemeshkevich1 , 1B.V. Petrovsky Russian Scientific Center of Surgery of the Russian Academy of Medical Sciences - Moscow - Russian Federation ,


Introduction. Recent advances in genetic technologies provide a new insight into molecular pathogenesis of the left ventricular hypertrophy and/or non-compaction. Clinical appearance of the single mutation can vary significantly in different families and even within the same affected pedigree. Genotype-phenotype correlation is poorly understood despite extensive study worldwide. 
Materials and methods. 
Cohort of patients. From 2009-2015 150 probands with hypertrophic cardiomyopathy (HCM) and 60 probands with LVNC had underwent genetic screening. 
Genetic analysis. Study was performed in accordance with the Helsinki declaration and the local ethics committee. Genetic screening of the targeted 10 genes (MYBPC3, TAZ, TPM1, LDB3, MYL2, ACTC1, MYL3, MYH7, TNNI3, and TNNT2) was performed by next generation sequencing followed by Sanger re-sequencing. Cascade familial screening was performed when available. De novo mutational status was counted only if genetic testing reveal absence of the genetic variant in both parents.
"Damaging" or "probably damaging" genetic variants were found in 39 HCM index cases (26%) what is less than expected. The vast majority of mutations were found in the MYH7 and MyBPC3 gene what fits with worldwide mutation rates. De novo origin was confirmed for 4 mutations (10% of all genotype-positive cases, and 2.6% in the whole HCM cohort). Three mutations had raised de novo in the MYH7 gene, and 1 probably damaging de novo variant was found in the TPM1 gene. Single de novo genetic variant in the MYH7 gene was found in the patient with familial HCM in addition to the known mutation in the MyBPC3 gene inherited from the affected mother. This patient had severe clinical phenotype and underwent reconstructive extended myectomy and ICD implantation at the age of 15 y.o. 
"Damaging" or "probably damaging" genetic variants were found in 14 LVNC index cases (23%). Mutations in the MYH7 gene were also the most common finding. De novo status was confirmed for 4 mutations in the MYH7 gene (29% of all genotype-positive cases, and 6.6% in the whole LVNC cohort). 
All carriers of de novo mutations had significantly younger age of clinical manifestation within own group. 
Totally 18 mutations in the MYH7 gene were detected in this study in the whole cohort of patients (HCM and LVNC), and five of them had raised de novo. 
Conclusion. Mutations de novo are responsible for a significant portion of the LVNC, and are less common but not negligible in HCM patients. Severe clinical phenotype within "mildly" affected family might be explained by additional de novo mutation (at least in some families). The MYH7 gene is an important source of de novo mutations maintaining the high prevalence of HCM and LVNC in population. 
Study limitation. 
We were unable to track mutation origin in half of the cases because of incomplete data from the families. So the real prevalence of de novo mutations might be underestimated.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are